Hemochromatosis cardiomyopathy

Article written and reviewed by Dr Luca Moretti

Hemochromatosis cardiomyopathy is the cardiac manifestation of iron overload sufficient to allow reactive iron to enter cardiomyocytes. The name should not be limited to HFE hemochromatosis alone: myocardial siderosis may result from non-HFE hereditary forms, chronic transfusions, ineffective erythropoiesis or, more rarely, other conditions that alter iron regulation. What defines cardiac disease is convergence between an overload cause, demonstration of tissue iron and a mechanical or electrical phenotype plausibly related to it.

The distinction is essential because elevated ferritin, an HFE genotype and cardiomyopathy can coexist without a causal relationship. Metabolic steatosis, alcohol, inflammation, malignancy and liver injury raise ferritin; hypertension, ischemia and valve disease explain heart failure far more often in the general population. Attributing the heart to iron without documenting it risks an improper diagnosis, whereas overlooking still-reversible siderosis loses one of the rare opportunities for etiologic recovery. Evidence of causality therefore comes from the entire pathway and not from a single blood value.

The heart may pass through a silent phase, diastolic dysfunction with still-normal chambers, arrhythmias or conduction disturbances, and finally dilated cardiomyopathy with systolic failure. The old stereotype of an exclusively restrictive form is therefore incomplete. Intensity, rate and distribution of accumulation vary with the biological defect, age, transfusions and previous therapy; in juvenile forms, heart disease may precede overt cirrhosis and become the dominant manifestation. The dynamic natural history explains why screening should precede symptoms.

Iron homeostasis and mechanism of injury

The body has no regulated pathway for eliminating large amounts of iron. Balance depends mainly on duodenal absorption and macrophage recycling, controlled by hepatic hepcidin. Hepcidin binds ferroportin and triggers its internalization, reducing iron transfer into plasma. In hereditary hemochromatosis, hepcidin production is inappropriately low relative to stores, or the ferroportin-hepcidin response is altered; the result is a persistent influx that progressively saturates transferrin. The regulatory defect precedes organ damage by years.

When transferrin capacity is exceeded, non-transferrin-bound iron and a labile, redox-active plasma fraction appear. These species enter cardiomyocytes even through channels not designed as selective iron transporters, accumulate in the cytosol, lysosomes and mitochondria, and fuel radical-generating reactions. Lipid peroxidation, protein damage, respiratory-chain dysfunction and altered calcium homeostasis reduce energy, relaxation and contractility. Redox toxicity is therefore more important than the mere histologic presence of pigment.

Ion channels, junctions and the conduction system are affected by the same oxidative environment. The consequences are repolarization heterogeneity, slowed conduction, abnormal automaticity and substrates for atrial fibrillation or ventricular tachycardia. Over time, cell death and fibrosis make part of the damage no longer dependent on removable iron. The reversible window lies before scar replaces a substantial proportion of myocardium, which is why a normal ejection fraction does not justify waiting if T2* is abnormal.

Distribution between liver and heart is not parallel. A patient may have major hepatic iron with myocardial sparing, or cardiac accumulation not predicted by current ferritin; in transfused patients, anemia type, duration, chelator and adherence matter. The liver receives and stores iron earlier, while the kinetics of entry into and exit from the heart differ. Organ discordance makes it inappropriate to use ferritin or liver concentration as an individual surrogate for myocardial iron.

Hereditary causes and secondary overload

HFE hemochromatosis associated with p.Cys282Tyr homozygosity is the most common hereditary form in populations of Northern European ancestry. Penetrance is incomplete: the genotype increases risk but is not equivalent to clinical disease, and many carriers do not develop organ damage. Sex, blood loss, alcohol, liver disease and metabolic factors modulate expression. The p.His63Asp or p.Ser65Cys variants, especially when isolated, should not be used to automatically explain severe overload. Contextualized genetics separates a common predisposition from a demonstrated phenotype.

Non-HFE forms include HJV and HAMP defects, often responsible for juvenile hemochromatosis, TFR2 variants and SLC40A1 abnormalities. Early onset, hypogonadism and disproportionate heart disease should prompt consideration particularly of a severe hepcidin-axis defect. Ferroportin disease is not uniform: some variants cause macrophage retention with only modestly elevated saturation, whereas others cause hepcidin resistance and a hemochromatosis-like phenotype. A targeted molecular panel is indicated after confirming overload and describing age, inheritance and biochemistry.

In transfusional overload, each unit of red blood cells introduces iron that cannot be physiologically eliminated. Transfusion-dependent thalassemias, sickle-cell disease, myelodysplastic syndromes and marrow failure differ, however, in intestinal absorption, inflammation, distribution and survival, so the same number of transfusions does not produce identical cardiac risk. Ineffective erythropoiesis also suppresses hepcidin and increases absorption. Cumulative iron balance integrates transfusions, losses, chelation and the biology of the hematologic disease.

Other causes include some hemolytic or sideroblastic anemias, excessive parenteral iron use and rare hepatic or metabolic conditions. So-called dysmetabolic hyperferritinemia generally presents with normal or only moderately elevated saturation and by itself does not justify a diagnosis of siderotic cardiomyopathy. Aceruloplasminemia also has a different tissue distribution and neurologic or diabetic manifestations. Etiologic classification is not a naming exercise: it determines whether to remove blood, chelate, treat erythropoiesis or search for a specific genetic disease.

Cardiac phenotype and systemic manifestations

The initial phase may be characterized by reduced exercise tolerance, inappropriate tachycardia or nonspecific relaxation abnormalities. Intracellular accumulation does not necessarily produce markedly thickened walls; modest concentric remodeling and diastolic dysfunction may occur, followed by increased volumes and reduced ejection fraction. Right-sided impairment may reflect both direct involvement and pulmonary hypertension or liver disease. The evolving phenotype should be read serially, because a single late image does not reveal the preceding phase.

Palpitations, atrial fibrillation or flutter, ectopy and ventricular tachycardia may occur before or together with heart failure. Sinus-node dysfunction and atrioventricular blocks are described, especially in advanced or juvenile forms, but no ECG pattern is specific. Syncope requires distinction among bradyarrhythmia, tachyarrhythmia, hypotension and low output. Electrical risk depends on active iron, fibrosis, ventricular function and clinical substrate and cannot be reduced to a biochemical threshold.

Hepatomegaly, abnormal liver enzymes, fibrosis, diabetes, hypogonadism, hypothyroidism, skin pigmentation and metacarpophalangeal arthropathy strengthen suspicion of systemic hemochromatosis. In chronic anemias, dyspnea and cardiomegaly may also result from high output, hypoxia, shunts, pulmonary hypertension or infections. A multiorgan interpretation avoids attributing every cardiac abnormality to deposition while also recognizing a juvenile form before liver damage becomes dominant.

Ischemic heart disease is not a specific and inevitable consequence of hemochromatosis. Diabetes, smoking, dyslipidemia and age retain their weight, and chest pain requires standard coronary reasoning. Alcohol and cirrhosis may also cause cardiomyopathy independently. A parallel differential diagnosis remains necessary even when iron is present, because two mechanisms may coexist and require distinct treatments.

From biochemical suspicion to etiologic diagnosis

The first level measures transferrin saturation and ferritin, ideally confirming a persistent abnormality and considering context. Saturation reflects the ratio between serum iron and binding capacity and rises early in hepcidin-deficiency forms; ferritin estimates stores but is an acute-phase protein. Complete blood count, transaminases, inflammatory markers, renal function, glucose and transfusion history complete interpretation. The combined iron profile is more informative than any isolated value.

According to EASL guidelines, in a C282Y homozygote a concordant increase in saturation and ferritin may support a diagnosis of hemochromatosis; in other genotypes, hepatic overload must be demonstrated by magnetic resonance or, in selected cases, biopsy, while excluding secondary causes. Indicative thresholds are not interchangeable with evidence of heart disease and should not be applied without accounting for sex, menopause, inflammation and laboratory methods. The diagnosis of hemochromatosis precedes but does not replace the diagnosis of cardiac involvement.

HFE testing is ordered when the profile is compatible and ancestry makes the common form plausible. A negative result does not automatically justify extended panels: hepatic iron, transfusions, anemia, alcohol and metabolic disease should first be verified. Very young age, recessive or dominant family history, severe burden with nondiagnostic HFE results and cardiac-endocrine manifestations select patients for non-HFE genetics. The diagnostic sequence reduces variants of uncertain significance and prevents the molecular laboratory from replacing the phenotype.

Liver magnetic resonance quantifies iron concentration and helps distinguish parenchymal from reticuloendothelial distributions; fibrosis assessment determines hepatic risk and surveillance. Liver biopsy is no longer routine but retains a role when etiology, fibrosis or concomitant diseases remain uncertain. Endomyocardial biopsy is rarely necessary because T2* measures iron noninvasively and sampling may not reflect the entire organ. The appropriate tissue test is the one that answers the clinical question with the least risk.

ECG, echocardiography and biomarkers

Baseline ECG and ambulatory monitoring assess atrial rhythm, conduction, ectopy and tachycardia. Voltages and repolarization may be abnormal, but there is no signature equivalent to T2*. Monitoring duration should be adapted to palpitations, syncope and the degree of heart disease; prolonged recording may be more useful than repeated Holters when events are rare. Rhythm surveillance should continue during iron removal because mechanical and electrical improvement do not occur simultaneously.

Echocardiography measures dimensions, ejection fraction, right ventricular function, pressures and valves. Doppler and strain may detect abnormalities before systolic dysfunction, but anemia, preload and heart rate influence results. A normal echocardiogram does not exclude siderosis; conversely, a dilated phenotype in a transfused patient does not prove that iron is the cause. Functional monitoring documents the effect on the heart, whereas magnetic resonance specifies the iron substrate.

Troponin and natriuretic peptides help define injury and congestion without measuring iron. Renal function, anemia, sepsis and arrhythmias can raise them. People receiving chelation also require complete blood count, creatinine, proteinuria, liver enzymes and drug-specific assessments; during phlebotomy, hemoglobin guides safety and frequency. The monitoring matrix combines iron-removal efficacy, organ function and treatment toxicity.

Cardiac magnetic resonance T2 star

Iron alters magnetic susceptibility and accelerates signal decay in gradient-echo sequences. The T2* time measured in the interventricular septum decreases as iron increases: at 1.5 tesla, using a validated methodology, values above about 20 ms are generally considered not indicative of significant overload, values between 10 and 20 ms suggest siderosis, and values below 10 ms identify high risk, particularly marked below 6 ms. These thresholds derive mainly from thalassemia and require standardized technique, not automatic transfer between different scanners and field strengths.

The study by Kirk and colleagues showed in thalassemia that cardiac T2* predicted heart failure and arrhythmias far better than ferritin and liver iron. This transformed management of transfusional overload, allowing chelation to be intensified before ejection fraction fell. However, a cohort prognostic threshold does not replace individual assessment: trends, function, symptoms, adherence and previous exposure remain determinants. Preclinical risk is the true value of the measurement.

Complete magnetic resonance includes volumes, function, cine imaging, possible LGE and mapping. LGE identifies scar but does not quantify iron; native T1 may decrease with iron but is not yet a universal substitute for T2*. Severe arrhythmia, devices or artifacts may limit quality. The report should state field strength, sequence, region and fitting method, and follow-up should be performed at the same center when possible. Longitudinal comparability is essential because a few milliseconds can change the risk category.

The frequency of monitoring depends on the value: a normal T2* and stable burden permit longer intervals; reduced values, a change in chelation or dysfunction require closer monitoring according to specialist protocols. Repeating a measurement too early is not useful if the biological time of iron removal does not allow an interpretable change, unless clinical deterioration occurs. Personalized timing avoids both false reassurance and tests without decision-making value.

Iron removal: phlebotomy and chelation

Therapeutic phlebotomy is the first-line treatment for hereditary hemochromatosis with overload in a person without anemia. The induction phase generally removes about 400-500 mL per session at an adapted frequency, monitoring hemoglobin and tolerance, until a ferritin target around 50 µg/L according to EASL; maintenance keeps it approximately 50-100 µg/L at individualized intervals. These targets do not justify indiscriminate depletion and should be modified in the presence of instability. Gradual mobilization reduces stores while iron slowly leaves organs.

In advanced heart failure, a standard blood draw may reduce preload and pressure poorly tolerated. Smaller volumes, longer intervals, close monitoring or a chelation phase may be discussed at experienced centers. The presence of heart disease makes iron removal more urgent, not safer to perform rapidly without control. Hemodynamic stability governs the pace and requires coordination among cardiology, hematology and hepatology.

Chelation is central in transfusional overload and in people with anemia or who cannot undergo phlebotomy. Parenteral deferoxamine, oral deferiprone and oral deferasirox have different pharmacology, evidence and toxicities; in severe cardiac iron, intensive strategies, sometimes combined, are used according to thalassemia protocols and individual characteristics. Neutropenia or agranulocytosis with deferiprone, renal or hepatic injury with deferasirox, and infusion-related or sensory problems with deferoxamine require surveillance. Chelator choice balances myocardial access, urgency, organs and real ability to adhere.

Therapy is not judged by the fall in ferritin alone. Transfusion exposure, liver concentration, T2*, cardiac function and toxicity must be followed; ferritin fluctuating because of infection does not by itself justify escalation or interruption. When transfusions continue, the objective is a sufficiently negative balance to protect organs, not simply normalization of a value. The multidimensional response avoids over-chelation and silent persistence of cardiac iron.

A balanced diet, avoiding iron supplements and high doses of unprescribed vitamin C, limiting alcohol when liver disease exists, and preventing infections from certain siderophilic bacteria are part of management. Extreme dietary restrictions have only modest effects compared with phlebotomy and may worsen nutrition. Raw shellfish should be avoided in clinical overload because of the risk of severe Vibrio infections. Practical prevention accompanies causal therapy without becoming punitive regimens.

Heart failure, arrhythmias and devices

Heart failure with reduced ejection fraction is treated according to guidelines with diuretics and neurohormonal therapy, adapting doses to blood pressure, kidney function and anemia. There is no robust evidence justifying withholding prognostic drugs solely because the cause is iron, but reversibility requires reassessment: pressure and function may change during removal. In the acute phase, decongestion, treatment of the precipitant and rapid intensification of iron therapy in an expert setting proceed together. Dual therapy supports the heart while removing the toxic agent.

Atrial fibrillation requires rhythm or rate control and anticoagulation assessment according to thromboembolic and bleeding risk. Ventricular tachycardia, syncope and cardiac arrest follow standard secondary-prevention principles; for primary-prevention ICD, ejection fraction, fibrosis and prognosis are considered, remembering that function may recover. A wearable defibrillator may be discussed in selected scenarios during a reversible phase but does not replace iron treatment. The electrical strategy should be reassessed after recovery and cannot wait when an established indication exists.

Symptomatic bradycardia and advanced block require pacing; in the presence of dysfunction and a high pacing percentage, a mode that avoids further dyssynchrony is evaluated. Ablation of atrial or ventricular arrhythmias may be appropriate despite an evolving metabolic substrate. Iron removal reduces risk but does not necessarily erase scar and circuits. The residual substrate explains why normalization of T2* does not always mean disappearance of the arrhythmologic indication.

Family, follow-up and prognosis

In confirmed HFE hemochromatosis, testing is offered to adult first-degree relatives, integrating genotype, saturation and ferritin. Indiscriminately testing minors for a common adult-onset predisposition is not equivalent to managing a juvenile form: HJV or HAMP may require early diagnosis and specific counseling. Family cascade testing identifies who needs surveillance without medicalizing those who carry only a low-impact allele.

Follow-up combines symptoms, physical examination, ECG, echocardiography, rhythm and CMR T2* when indicated. Frequency and content are adapted to cause, initial measurement, transfusion burden and response; endocrinology, hepatology, hematology and genetics follow other organs. In a form treated early, intervals may lengthen, whereas a very low T2*, arrhythmias or therapeutic changes require a close network. Integrated surveillance prevents both recurrent iron accumulation and noncardiac complications.

The prognosis of cardiac siderosis has changed with magnetic resonance and chelation. Even severe dysfunction may improve if iron is removed before irreversible fibrosis, but recovery is not immediate and arrhythmic risk persists during the transition. In common hereditary forms, preventing damage is generally easier than reversing it; in juvenile and transfusional forms, the pace requires expert centers. Conditional reversibility is the central message: real and clinically important, but dependent on time and treatment quality.

Communication should distinguish three levels: genetic variant, systemic overload and cardiomyopathy. Telling an HFE carrier with inflammatory ferritin that they have cardiac disease creates alarm; telling a transfused patient with reduced T2* and normal ejection fraction that the heart is healthy creates the opposite risk. A stratified diagnosis describes what has been demonstrated, what is probable and what information is missing, turning complex tests into verifiable decisions.

Pregnancy and the peripartum period require a specific plan. In carriers of common hemochromatosis, iron is not removed automatically and any phlebotomy depends on documented overload, hemoglobin and gestational stage; in transfusion-dependent anemias, interruption or modification of chelators should be agreed before conception. Ventricular function, arrhythmias and drugs determine obstetric risk. Preconception planning prevents both unnecessary depletion and months of iron exposure without an alternative.

Even after stores normalize, cirrhosis, diabetes, arthropathy and myocardial scar may persist and require their own follow-up. Maintenance prevents new accumulation but does not automatically erase hepatocellular risk in those with advanced fibrosis or arrhythmic risk in those with persistent LGE. Organ memory distinguishes correction of iron balance from healing its consequences and makes it necessary to document initial damage before therapy alters its markers.